Skip to main content
SpringerLink
Log in

Retracted: Oral Potentially Malignant Disorders

  • Chapter
  • First Online:
Book cover Contemporary Oral Oncology

  • 1047 Accesses

Abstract

The World Health Organization (WHO) workshop in 2005 redefined all oral lesions with a potential for a malignant transformation to be grouped under the title “potentially malignant disorders.” The traditional terminologies of premalignant lesions and premalignant conditions have been abandoned. There are several lesions that fall under this title; however we will limit our discussion to the most commonly seen lesions in clinical practice; these include lichen planus, leukoplakia, erythroplakia, erythroleukoplakia, erythroplakia with ulceration, proliferative verrucous leukoplakia, and submucous fibrosis. All the aforementioned lesions are predominantly found in the oral cavity. Potentially malignant lesions of the skin can also be found in the head and neck and however are beyond the scope of this chapter and will not be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Change history

  • 28 May 2020

    Chapter [7] has been retracted by the publisher. The chapter contains sections that substantially overlap with the following articles [2,3]. All authors agree to the retraction.

Bibliography

  1. Silverman Jr S, Bahl S. Oral lichen planus update: clinical characteristics, treatment responses, and malignant transformation. Am J Dent. 1997;10(6):259–63.

    PubMed  Google Scholar 

  2. Silverman Jr S, et al. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1991;72(6):665–70.

    Article  PubMed  Google Scholar 

  3. Kawamura E, et al. Accumulation of oligoclonal T cells in the infiltrating lymphocytes in oral lichen planus. J Oral Pathol Med. 2003;32(5):282–9.

    Article  CAS  PubMed  Google Scholar 

  4. Iijima W, et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol. 2003;163(1):261–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Femiano F, et al. Recent advances on the pathogenesis of oral lichen planus (OLP). The adhesion molecules. Minerva Stomatol. 1999;48(4):151–9.

    CAS  PubMed  Google Scholar 

  6. Demitsu T, et al. Corticosteroid-resistant erosive oral lichen planus successfully treated with topical cyclosporine therapy. Int J Dermatol. 2000;39(1):79–80.

    Article  CAS  PubMed  Google Scholar 

  7. Eisen D. The clinical manifestations and treatment of oral lichen planus. Dermatol Clin. 2003;21(1):79–89.

    Article  PubMed  Google Scholar 

  8. De Rossi SS, Ciarrocca K. Oral lichen planus and lichenoid mucositis. Dent Clin North Am. 2014;58(2):299–313.

    Article  PubMed  Google Scholar 

  9. Rhodus NL, Myers S, Kaimal S. Diagnosis and management of oral lichen planus. Northwest Dent. 2003;82(2):17–9, 22–5.

    PubMed  Google Scholar 

  10. Kuffer R, Lombardi T. Erosion and ulceration occurring on oral lichen planus. Comments on the article ‘Erosive lichen planus: what is this?’ by A. Rebora. Dermatology. 2003;207(3):340.

    Article  PubMed  Google Scholar 

  11. Brouns ER, et al. The relevance of uniform reporting in oral leukoplakia: definition, certainty factor and staging based on experience with 275 patients. Med Oral Patol Oral Cir Bucal. 2013;18(1):e19–26.

    Article  PubMed  Google Scholar 

  12. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36(10):575–80.

    Article  CAS  PubMed  Google Scholar 

  13. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol. 2003;39(8):770–80.

    Article  PubMed  Google Scholar 

  14. Schepman KP, et al. Prevalence study of oral white lesions with special reference to a new definition of oral leucoplakia. Eur J Cancer B Oral Oncol. 1996;32B(6):416–9.

    Article  CAS  PubMed  Google Scholar 

  15. Abidullah M, et al. Leukoplakia – review of a potentially malignant disorder. J Clin Diagn Res. 2014;8(8):ZE01–4.

    PubMed  PubMed Central  Google Scholar 

  16. Schepman KP, et al. Tobacco usage in relation to the anatomical site of oral leukoplakia. Oral Dis. 2001;7(1):25–7.

    Article  CAS  PubMed  Google Scholar 

  17. Freitas MD, et al. Clinicopathologic aspects of oral leukoplakia in smokers and nonsmokers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(2):199–203.

    Article  PubMed  Google Scholar 

  18. Hashibe M, et al. Alcohol drinking, body mass index and the risk of oral leukoplakia in an Indian population. Int J Cancer. 2000;88(1):129–34.

    Article  CAS  PubMed  Google Scholar 

  19. Ram H, et al. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg. 2011;10(2):132–7.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Silverman S. Oral cancer. Semin Dermatol. 1994;13(2):132–7.

    CAS  PubMed  Google Scholar 

  22. Zengel P, et al. Cancer of unknown primary originating from oropharyngeal carcinomas are strongly correlated to HPV positivity. Virchows Arch. 2012;461(3):283–90.

    Article  PubMed  Google Scholar 

  23. Krisanaprakornkit S, Iamaroon A. Epithelial-mesenchymal transition in oral squamous cell carcinoma. ISRN Oncol. 2012;2012:681469.

    PubMed  PubMed Central  Google Scholar 

  24. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.

    Article  CAS  PubMed  Google Scholar 

  25. Bedi GC, et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res. 1996;56(11):2484–7.

    CAS  PubMed  Google Scholar 

  26. Braakhuis BJ, et al. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63(8):1727–30.

    CAS  PubMed  Google Scholar 

  27. Vedtofte P, et al. Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg. 1987;16(6):656–64.

    Article  CAS  PubMed  Google Scholar 

  28. Ishii J, Fujita K, Komori T. Clinical assessment of laser monotherapy for squamous cell carcinoma of the mobile tongue. J Clin Laser Med Surg. 2002;20(2):57–61.

    Article  PubMed  Google Scholar 

  29. van der Hem PS, et al. The results of CO2 laser surgery in patients with oral leukoplakia: a 25 year follow up. Oral Oncol. 2005;41(1):31–7.

    Article  PubMed  Google Scholar 

  30. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer. 1975;36(3):1021–8.

    Article  CAS  PubMed  Google Scholar 

  31. Reichart PA, Philipsen HP. Oral erythroplakia – a review. Oral Oncol. 2005;41(6):551–61.

    Article  PubMed  Google Scholar 

  32. Tung CL, et al. Proteomics-based identification of plasma biomarkers in oral squamous cell carcinoma. J Pharm Biomed Anal. 2013;75:7–17.

    Article  CAS  PubMed  Google Scholar 

  33. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45(4–5):317–23.

    Article  PubMed  Google Scholar 

  34. Mashberg A, Samit A. Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. CA Cancer J Clin. 1995;45(6):328–51.

    Article  CAS  PubMed  Google Scholar 

  35. Rhodus NL, Kerr AR, Patel K. Oral cancer: leukoplakia, premalignancy, and squamous cell carcinoma. Dent Clin North Am. 2014;58(2):315–40.

    Article  PubMed  Google Scholar 

  36. Mashberg A. Diagnosis of early oral and oropharyngeal squamous carcinoma: obstacles and their amelioration. Oral Oncol. 2000;36(3):253–5.

    Article  CAS  PubMed  Google Scholar 

  37. Silverman Jr S, Gorsky M. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(2):154–7.

    Article  PubMed  Google Scholar 

  38. Palefsky JM, et al. Association between proliferative verrucous leukoplakia and infection with human papillomavirus type 16. J Oral Pathol Med. 1995;24(5):193–7.

    Article  CAS  PubMed  Google Scholar 

  39. Hansen LS, Olson JA, Silverman Jr S. Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Oral Med Oral Pathol. 1985;60(3):285–98.

    Article  CAS  PubMed  Google Scholar 

  40. Lee SY, et al. Relevance of human papilloma virus (HPV) infection to carcinogenesis of oral tongue cancer. Int J Oral Maxillofac Surg. 2010;39(7):678–83.

    Article  CAS  PubMed  Google Scholar 

  41. Hillbertz NS, et al. Viral and molecular aspects of oral cancer. Anticancer Res. 2012;32(10):4201–12.

    CAS  PubMed  Google Scholar 

  42. Femiano F, Gombos F, Scully C. Oral proliferative verrucous leukoplakia (PVL); open trial of surgery compared with combined therapy using surgery and methisoprinol in papillomavirus-related PVL. Int J Oral Maxillofac Surg. 2001;30(4):318–22.

    Article  CAS  PubMed  Google Scholar 

  43. Schoelch ML, et al. Laser management of oral leukoplakias: a follow-up study of 70 patients. Laryngoscope. 1999;109(6):949–53.

    Article  CAS  PubMed  Google Scholar 

  44. Schwartz J. Atrophia idiopathica mucosae oris. London: Demonstrated at the 11th Int Dent Congress; 1952.

    Google Scholar 

  45. Joshi SG. Fibrosis of the palate and pillars. Indian J Otolaryngol. 1953;4:1.

    Google Scholar 

  46. Jacob BJ, et al. Betel quid without tobacco as a risk factor for oral precancers. Oral Oncol. 2004;40(7):697–704.

    Article  PubMed  Google Scholar 

  47. Canniff JP, Harvey W. The aetiology of oral submucous fibrosis: the stimulation of collagen synthesis by extracts of areca nut. Int J Oral Surg. 1981;10 Suppl 1:163–7.

    CAS  PubMed  Google Scholar 

  48. Murti PR, et al. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol. 1985;13(6):340–1.

    Article  CAS  PubMed  Google Scholar 

  49. Kakar PK, Puri RK, Venkatachalam VP. Oral submucous fibrosis – treatment with hyalase. J Laryngol Otol. 1985;99(1):57–9.

    Article  CAS  PubMed  Google Scholar 

  50. Haque MF, et al. Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis. J Oral Pathol Med. 2001;30(1):12–21.

    Article  CAS  PubMed  Google Scholar 

  51. Epstein JB, et al. Defining the risk of oral premalignant lesions. Oral Oncol. 2009;45(3):297–8.

    Article  Google Scholar 

  52. Holmstrup P, et al. Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006;42(5):461–74.

    Article  CAS  PubMed  Google Scholar 

  53. Holmstrup P, et al. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med. 2007;36(5):262–6.

    Article  CAS  PubMed  Google Scholar 

  54. Roed-Petersen B. Effect on oral leukoplakia of reducing or ceasing tobacco smoking. Acta Derm Venereol. 1982;62:164–7.

    CAS  PubMed  Google Scholar 

  55. Chad Martin G, Brown JP, Eifler CW, Houston GD. Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc. 1999;130:945–54.

    Article  Google Scholar 

  56. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol. 1994;12(4):851–73.

    Article  CAS  PubMed  Google Scholar 

  57. Kuriakose MA, Sharan R. Oral cancer prevention. Oral Maxillofac Surg Clin North Am. 2006;18(4):493–511.

    Article  PubMed  Google Scholar 

  58. Forastiere A, et al. Head and neck cancer. N Engl J Med. 2001;345(26):1890–900.

    Article  CAS  PubMed  Google Scholar 

  59. Ribeiro AS, Salles PR, da Silva TA, et al. Review of the nonsurgical treatment of oral leukoplakia. Int J Dentistry. 2010;1155:1–10.

    Article  Google Scholar 

  60. Lodi G, Franchini R, Warnakulasurya S, et al. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev. 2015;(7).

    Google Scholar 

  61. Hong WK, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315(24):1501–5.

    Article  CAS  PubMed  Google Scholar 

  62. Benner SE, Lippman SM, Hong WK. Retinoid chemoprevention of second primary tumors. Semin Hematol. 1994;31(4 Suppl 5):26–30.

    CAS  PubMed  Google Scholar 

  63. Toma S, et al. Biological aspects and perspectives applicable to the chemoprevention of cancer of the upper respiratory-digestive tract. Acta Otorhinolaryngol Ital. 1990;10 Suppl 27:41–54.

    CAS  PubMed  Google Scholar 

  64. Chiesa F, et al. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer B Oral Oncol. 1992;28B(2):97–102.

    Article  CAS  PubMed  Google Scholar 

  65. Nagao T, et al. Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: A randomized controlled trial. Int J Cancer. 2015;136(7):1708–17.

    Article  CAS  PubMed  Google Scholar 

  66. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol. 1976;25(15):1811–2.

    Article  CAS  PubMed  Google Scholar 

  67. Toda S, et al. Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull (Tokyo). 1985;33(4):1725–8.

    Article  CAS  Google Scholar 

  68. Ruby AJ, et al. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 1995;94(1):79–83.

    Article  CAS  PubMed  Google Scholar 

  69. Kawamori T, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 1999;59(3):597–601.

    CAS  PubMed  Google Scholar 

  70. Pereira MA. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs. Adv Exp Med Biol. 1999;470:55–63.

    Article  CAS  PubMed  Google Scholar 

  71. Pereira MA, et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis. 1996;17(6):1305–11.

    Article  CAS  PubMed  Google Scholar 

  72. Tao L, Li K, Pereira MA. Chemopreventive agents-induced regression of azoxymethane-induced aberrant crypt foci with the recovery of hexosaminidase activity. Carcinogenesis. 1997;18(7):1415–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oral/Head and Neck Oncologic and Reconstructive Surgery, North Memorial Medical Center, 3366 Oakdale Ave North, Robbinsdale, MN, 55422, USA

    Ketan Patel DDS, PhD & Deepak Kadamani DMD, MD, FACS

  2. Department of Head and Neck, Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA

    Moni Abraham Kuriakose MD, FRCS

Authors
  1. Ketan Patel DDS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak Kadamani DMD, MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Moni Abraham Kuriakose MD, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepak Kadamani DMD, MD, FACS .

Editor information

Editors and Affiliations

  1. Department of Head and Neck, Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, Buffalo, USA

    Moni Abraham Kuriakose

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Patel, K., Kadamani, D., Kuriakose, M.A. (2017). Retracted: Oral Potentially Malignant Disorders. In: Kuriakose, M.A. (eds) Contemporary Oral Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-14911-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14911-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14910-3

  • Online ISBN: 978-3-319-14911-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation